Posts by molly wheeler
Why Testing for 7-Hydroxymitragynine Matters: Understanding the Emerging Risk Behind Kratom Products
Author: Jordan Kelsey Kratom has been circulating for years in the wellness and supplement space, often marketed as an herbal energy booster or natural pain reliever. But recently, it has surged back into national headlines—especially as the Beshear administration announced movement toward classifying 7‑hydroxymitragynine (7-HMG) as a Schedule I controlled substance in Kentucky This…
Read MoreNew Hire – Chris Roberts – Vice President of Strategic Initiatives
We are pleased to announce that Chris Roberts will be joining #teamgravity as our Vice President of Strategic Initiatives. In this role, Chris will report directly to Tony Remington, Co-Founder & CEO, and be responsible for compliantly increasing testing volumes through strategic programming and partnerships. He will administer and manage growth-focused projects in collaboration with…
Read MoreUK St. Claire and Gravity Diagnostics to Enhance Substance Use Disorder Recovery with Advanced Toxicology Diagnostic Services
Morehead, KY – [12/19/24] – UK St. Claire will contract with Gravity Diagnostics for comprehensive and compliant toxicology diagnostic services to patients. After a competitive and selective bidding process, Gravity Diagnostics was selected to work with UK St. Claire to further strengthen efforts to support substance use disorder (SUD) recovery across the region. UK St.…
Read MoreGravity Diagnostics: An In-Network Provider with All MCOs in Kentucky!
Gravity Diagnostics is proud to be an in-network provider with all Managed Care Organizations (MCOs) in the state of Kentucky, including WellCare, Anthem, Aetna, Humana, Molina, and UnitedHealthcare. This underscores our commitment to ensuring high-quality diagnostic services are accessible to everyone in our community. Enhanced Access to Care As an in-network provider, we…
Read More2024 National Drug Threat Assessment and Gravity Diagnostics’ Trending Data
Authors: Nicholas Lyktey, Chief of Laboratory Operations, and Jordan Kelsey, Clinical Product Specialist The Drug Enforcement Administration (DEA) released the 2024 National Drug Threat Assessment, which contains a comprehensive assessment of illicit drug threats and traffic trends in the United States. Gravity Diagnostics’ Team continues to be proactively educated on new drug trends and add…
Read MoreXylazine: Still a Threat
Author: Dr. JP Canner, Ph.D., NRCC, MT(AAB) Xylazine: Still a Threat In April 2023, Xylazine was designated as an emerging threat to the United States after a series of reports from the FDA (Food and Drug Administration) and DEA (Drug Enforcement Administration). (1) While the dangers of Xylazine have been documented, the prevalence of…
Read More